In a meta-analysis of 57 studies, Zolgensma achieved a 95% survival rate and reduced the number of patients requiring ...

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

Preserving the ability to swallow reduces the need for invasive interventions and lowers the risk of life-threatening ...

Meanwhile, access to Zolgensma in the UK has been suspended in children older than 12 completed months, as there have been a "small number" of cases of liver-related side effects among children ...

Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...

By Mariam Sunny (Reuters) -Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to ...

The application for Zolgensma was approved at the Central Social Insurance Medical Council, an advisory council for the health minister, on May 13 and will go into effect on May 20.

We simply can't afford it," says Zeba Gufran, their mother. Zolgensma gene therapy, which the Gufrans want to try, is one of the most expensive drugs in the world. It is given as a one-time dose ...

Zolgensma was found in a real-world study to ease breathing difficulties in children with SMA and reduce respiratory-related ...

FDA Approval of Zolgensma, first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), has become a milestone in the treatment of patients with SMA. It ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.